Type 2 innate lymphoid cells are not involved in mouse bladder tumor development

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Bladder cancer therapies face limitations due to side effects and treatment failures, necessitating the identification of novel therapeutic targets.
• Innate lymphoid cells (ILCs), particularly type 2 innate lymphoid cells (ILC2s), play a crucial role in modulating the tumor microenvironment and anti-tumor immune responses.

Purpose of the Study:

• To investigate the role of ILC2s in bladder tumor development and progression.
• To determine if ILC2s represent a viable therapeutic target for bladder cancer.

Main Methods:

• Utilized the orthotopic murine MB49 bladder tumor model for in vivo studies.
• Analyzed ILC subset populations (ILC1s and ILC2s) in tumor-bearing bladders.
• Employed genetic and pharmacological strategies to target ILC2s, including IL-4/IL-13 signaling blockade, IL-5 or IL-33 receptor inhibition, and the use of IL-33-deficient or ILC2-deficient mice.

Main Results:

• ILC2s were found to be enriched in the bladder under normal conditions, similar to the lung.
• Tumor growth led to an increase in ILC1s but did not alter ILC2 populations.
• Targeting ILC2s through various methods did not impact the survival of mice with bladder tumors.

Conclusions:

• ILC2s do not appear to play a significant role in the development or progression of bladder tumors in this murine model.
• These findings suggest that ILC2s may not be a promising therapeutic target for bladder cancer.
• Further investigation in human bladder cancer patients is warranted to validate these results.